« Return to News | Miscellaneous

PRA International Completes Buyout

Thursday, December 13, 2007 12:58 PM

Genstar Capital, a private equity group based in San Francisco, has completed its acquisition of PRA International, paying $797 million for the Raleigh, N.C.-based contract research organization (CRO).

During a conference call in July, PRA executives said that Genstar will invest in the company to accelerate plans for expanding the firm’s service offerings and broaden its geographic footprint.

In response to an analyst’s question during the call, Terrance Bieker, chief executive officer of PRA, stated its board of directors came to the conclusion that the right course of action was to provide its shareholders with an immediate premium on their investment.

“This decision is driven by value and reward, and it was determined that this is a right price for the shareholders. So, the decision for doing this is not so the company can perform better in a different venue, it was done because it is a very good return to the shareholders,” Bierker said.

Shareholders will receive a cash buyout of $30.50 per common share. That would be a 24% premium over PRA’s average closing price for three months prior to the July announcement.

Genstar was an early investor in PRA and already owned 12.8% of the company. In June 2001, PRA’s executive management team completed a buyout of the company, partly with financial backing from Genstar. The company went public in November 2004.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2012 CenterWatch.